Catherine Mezzacappa

Dr. Catherine Mezzacappa


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2024 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
CMCatherine Mezzacappa
Catherine Mezzacappa
POPedro Ochoa-Allemant
Pedro Ochoa-Allemant
MSMarina Serper
Marina Serper
TTTamar H. Taddei
Tamar H. Taddei
BJBinu V. John
Binu V. John
NMNadim Mahmud
Nadim Mahmud

2 December 2024 in Hepatology
Verified
Journal Article
Open access
PVPhilip Vutien
Philip Vutien
AGAbbey Barnard Giustini
Abbey Barnard Giustini
NKNicole J. Kim
Nicole J. Kim
AMAndrew M. Moon
Andrew M. Moon
CHChun-Nan Hsu
Chun-Nan Hsu
GIGeorge N. Ioannou
George N. Ioannou
Background and Aims: Recently proposed “Rule-of-Five” criteria define compensated advanced chronic liver disease (cACLD) and clinically significant portal hypertension (CSPH) using liver stiffness (LS) and platelet count. We aimed to validate these criteria by determining whether they are associated with risk of adverse outcomes. Methods and Results: Patients without prior hepatic decompensation or hepatocellular carcinoma (HCC) who underwent LS and platelet measurements (n=17,076), were categorized as follows: no cACLD (LS 2.5-9.9 kPa); probable cACLD (LS 10-14.9 kPa); certain cACLD-no CSPH (LS 15-19.9 kPa and platelets ≥110,000/µL or LS 20-24.9 kPa and platelets ≥150,000/µL); probable CSPH (LS 15-19.9 kPa and platelets <110,000/µL or LS 20-24.9 and platelets <150,000/µL); and certain CSPH (LS ≥25 Kpa), which we further sub-divided into 25-49.9 kPa and 50-75 kPa. During a median follow-up of 2.82 years, each increase in “Rule-of-Five” category was associated linearly with higher risks of death (hazard ratio [HR] 1.22, 95% CI 1.18-1.25) and decompensation (HR 1.52, 95% CI 1.46-1.58). Compared to patients with LS 25-49.9 kPa, those with LS 50-75 kPa (“critical” CSPH) had approximately double the risk of decompensation (11.24 vs. 4.20 per 100 patient-years) and death (9.85 vs. 6.98 per 100 patient-years). Conclusions: The Baveno VII “Rule-of-Five” criteria provide a valid system for stratifying risks of death and hepatic decompensation and should be used routinely in patients with chronic liver disease. Among patients with CSPH (LS ≥25 kPa), the subgroup with LS 50-75 kPa (“critical” CSPH) has approximately double the risk of death and hepatic decompensation than LS 25-49.9 kPa. Export

1 July 2024 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
CMCatherine Mezzacappa
Catherine Mezzacappa
NKNicole J. Kim
Nicole J. Kim
PVPhilip Vutien
Philip Vutien
DKDavid E. Kaplan
David E. Kaplan
GIGeorge N. Ioannou
George N. Ioannou
TTTamar H. Taddei
Tamar H. Taddei
Importance: The risk of hepatocellular carcinoma (HCC) declines over time after hepatitis C virus (HCV) cure by direct-acting antiviral (DAA) therapies. Liver society guidelines recommend continuing HCC screening for these patients, but data on screening outcomes are lacking.Objective: To evaluate the association of HCC screening after HCV cure with overall survival.Design, Setting, and Participants: This cohort study evaluated patients with HCV cirrhosis who achieved DAA-induced HCV cure in the Veterans Affairs health care system between January 2014 and December 2022. Data analysis occurred from October 2023 to January 2024.Exposures: The percentage of time spent up to date with recommended HCC screening was calculated by year of follow-up and during the 4 years preceding HCC diagnosis (the detectable asymptomatic phase).Main Outcomes and Measures: The primary outcome was overall survival after HCC diagnosis and was compared by percentage of time spent up to date with screening using Kaplan-Meier analyses and Cox proportional hazards regression. Early-stage HCC at diagnosis and curative treatment were secondary outcomes assessed using logistic regression.Results: A total of 16 902 individuals were included (median [IQR] age, 64.0 [60.5-67.4] years; 16 426 male [97.2%]), of whom 1622 developed HCC. The cumulative incidence of HCC declined from 2.4% (409 of 16 902 individuals) to 1.0% (27 of 2833 individuals) from year 1 to year 7 of follow-up. Being up to date with screening for at least 50% of time during the 4 years preceding HCC diagnosis was associated with improved overall survival (log-rank test of equality over strata P = .002). In multivariate analysis, each 10% increase in follow-up spent up to date with screening was associated with a 3.2% decrease in the hazard of death (hazard ratio, 0.97; 95% CI, 0.95-0.99). There was a statistically significant interaction between time since HCV cure and screening, with no association observed among those who received a diagnosis of HCC more than 5 years after HCV cure. Each 10% of time spent up to date with screening was associated with a 10.1% increased likelihood of diagnosis with early-stage HCC (95% CI, 6.3%-14.0%) and a 6.8% increased likelihood of curative treatment (95% CI, 2.8%-11.0%).Conclusions and Relevance: In this cohort study of persons with HCV-related cirrhosis who achieved HCV cure and subsequently developed HCC, remaining up to date with screening was associated with improved overall survival, supporting the screening of eligible individuals.

3 December 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CMCatherine Mezzacappa
Catherine Mezzacappa
NRNeal G. Ravindra
Neal G. Ravindra
CCCesar Caraballo
Cesar Caraballo
FCFouad Chouairi
Fouad Chouairi
PMP. Elliott Miller
P. Elliott Miller
TATariq Ahmad
Tariq Ahmad
Importance: Patient outcomes in heart failure clinical trials are generally better than those observed in real-world settings. This may be related to stricter inclusion and exclusion criteria in clinical trials. Objective: We study sought to characterize the clinical implications of differences between patients in clinical trials and those in a real-world registry of patients receiving left ventricular assist devices (LVADs). Design, setting, and participants: This retrospective cohort study included all patients in INTERMACS (the Interagency Registry for Mechanically Assisted Circulatory Support) who were implanted with an axial flow LVAD from 2010 to 2015 to allow for equivalent comparisons. Main outcomes and measures: Differences in patient characteristics and 2-year rates of adverse outcomes with those reported in the ENDURANCE and MOMENTUM 3 clinical trials. Survival analyses were used to assess the relationships between prespecified patient factors and clinical outcomes. Results: Of the 10,937 LVAD recipients identified in INTERMACS between 2010–2015, 44% met at least 1 clinical trial exclusion criterion. The 2-year incidence of stroke and death amongst LVAD recipients in INTERMACS and the landmark clinical trials differed significantly (P<0.04, both). Nevertheless, patients who would have been excluded from the clinical trials did not have dramatically different 2-year mortality outcomes in INTERMACS [2y survival estimate: 66.4%, 95% CI (64.9–67.9%) versus 71.9%, 95% CI (70.6–73.1%)]. Clinical interventions driving a significantly increased risk of death were relatively rare (<5% of implants) and included mechanical ventilation, ECMO, severe thrombocytopenia, and dialysis. Conclusions and relevance: Most exclusion criteria used in LVAD clinical trials did not afford a substantially greater risk to patients in the real-world setting. In the relatively infrequent cases of end stage renal disease, thrombocytopenia, respiratory failure, and need for ECMO, the risks and benefits of LVAD therapy need careful weighting and further study.

1 December 2023 in Hepatology Communications
Verified
Journal Article
Open access
CMCatherine Mezzacappa
Catherine Mezzacappa
NMNadim Mahmud
Nadim Mahmud
MSMarina Serper
Marina Serper
BJBinu V. John
Binu V. John
TTTamar H. Taddei
Tamar H. Taddei
DKDavid Edward Kaplan
David Edward Kaplan
Background: Diabetes is associated with HCC; however, the impact of longitudinal blood glucose (BG) control on HCC risk in cirrhosis is not well known. We investigated this knowledge gap in a cohort of United States Veterans with cirrhosis from 2015 to 2021. Methods: We used repeated hemoglobin A1c measurements to categorize follow-up time according to BG control (defined as hemoglobin A1c < 7%) state over time: uncontrolled, nonsustained control (≤2 y), or sustained control (>2 y). We performed a sensitivity analysis using hemoglobin A1c < 8% to define BG control. We used Fine and Gray Cox proportional hazards regression with death and transplant as competing events to compare rates of incident HCC. Results: Our study included 81,907 individuals, 56.2% of whom had diabetes at baseline. There were 8,002 incident HCCs. The rate of HCC was 18% higher in diabetes (95% CI: 13% – 24%), and the relative increase in the rate of HCC varied by etiology of cirrhosis from nonsignificant (HCV) to an increase of 120% (HBV). Uncontrolled and nonsustained BG control was associated with 1.80 (95% CI: 1.70–1.91) and 2.34 (95% CI: 2.21–2.48) times the rate of HCC compared to sustained BG control, respectively. Using Hgb A1c < 8% to define BG control, HCC rates in uncontrolled and nonsustained BG control were 2.43 (2.28–2.58) and 2.23 (2.11–2.36) times that observed in sustained BG control. Conclusions: Associations between diabetes and HCC in cirrhosis vary according to the longitudinal BG control state. Inadequate BG control is consistently associated with a higher risk of HCC, and long-term BG control should be considered in comprehensive cirrhosis care. Export

16 January 2025 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
BJBinu V. John
Binu V. John
DBDustin Bastaich
Dustin Bastaich
CMCatherine Mezzacappa
Catherine Mezzacappa
RFRaphaella De Paula Ferreira
Raphaella De Paula Ferreira
AHAusten Hentschel
Austen Hentschel
BDBassam Dahman
Bassam Dahman
INTRODUCTION: Although metabolic dysfunction-associated steatotic liver disease (MASLD) and MASLD with increased alcohol intake (MetALD) are identified as clinical entities; tools to identify patients from electronic health records (EHRs) to perform large outcome studies are lacking. METHODS: In this retrospective study of participants from the Veterans Analysis of Liver Disease cohort assembled from 1/1/2013 to 12/31/2022, a rule-based natural language processing (NLP) algorithm searched EHRs for imaging evidence of hepatic steatosis. This was combined with identification of cardiometabolic risk factors and harmful alcohol use. Algorithm-derived diagnoses of MASLD, MetALD, alcohol-associated steatotic liver disease (ALD), and no steatotic liver disease (SLD) were validated using a blinded review of randomly selected charts. RESULTS: Among 817,657 eligible veterans, SLD was present in over half (n = 438,209, 53.5%), including MASLD in 299,259 (36.5%), 99,163 with MetALD (12.1%), and 38,552 (4.7%) with ALD. The NLP algorithm had a high correlation with steatosis on chart review, with a κ of 0.86 (95% CI 0.82–0.90), sensitivity of 0.96, and specificity of 0.90. Classification of MASLD, MetALD, ALD, and no SLD by the algorithm also showed high correlation with chart review, with a κ of 0.87 (95% CI 0.82–0.91). This algorithm identified 299,259 (36.5%) of the study cohort with MASLD, compared with 23,218 patients (2.8%) identified using I nternational Classification of D iseases-9/10 codes. DISCUSSION: An algorithm combining rule-based NLP with cardiometabolic risk factors and alcohol use from EHRs accurately identifies and classifies SLD and can be applied in large epidemiologic studies of SLD in the Veterans Health Administration.